PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2064448
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2064448
According to Mordor Intelligence, the u.S. specialty medical chairs market size is projected to be USD 1.74 billion in 2025, USD 1.86 billion in 2026, and reach USD 2.64 billion by 2031, growing at a CAGR of 7.20% from 2026 to 2031.

This report is Segmented by Product Type (Examination, Treatment, Rehabilitation), Technology (Manual, Hydraulic, Fully Electric, Connected Electric), End User (Hospitals, Dental Practices and DSOs, Ascs, Dialysis Centers, and More), and Clinical Application (Dental, Ophthalmic, ENT, Dialysis, Infusion, OB/GYN, and More). Forecasts are in Value (USD).
CMS has removed 285 musculoskeletal procedures from its Inpatient-Only list for CY 2026 and added 560 procedures to the ASC Covered Procedures List, accelerating the shift of treatment volumes to ambulatory settings. Medicare facility payments to ASCs are projected to reach USD 9.2 billion in 2026, with ASC surgical procedures per fee-for-service Medicare beneficiary increasing by 3.4% in 2024. This shift is driving demand in the United States specialty medical chairs market for versatile, programmable electric platforms that support multi-procedure workflows and optimize outpatient room layouts.
The aging population in the United States, projected to reach 88.8 million by 2060, is increasing the need for medical chairs designed for mobility challenges, transfer difficulties, and fall prevention. With 53% of Medicare beneficiaries aged 65-74 managing three or more chronic conditions, facilities are replacing older fixed-height chairs with models offering safer transfers and longer treatment support, broadening demand geographically and extending replacement cycles.
Fully electric specialty exam chairs in ophthalmic applications are priced between USD 5,850 and USD 11,650, while dental chairs range from USD 6,300 to USD 11,650. Fixed phlebotomy seating is more affordable, priced between USD 400 and USD 1,300. Redesigning products to meet the 17-inch low transfer height standard could increase manufacturer costs by 20% to 30%, creating a financial gap between large health systems and smaller clinics with limited budgets. Compliance pressures remain high, as federally funded providers must meet accessibility standards by July 8, 2026. Demand in the United States specialty medical chairs market is steady at the compliance threshold, but broader upgrades are constrained by budget limitations.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Treatment chairs are projected to grow at an 8.20% CAGR through 2031, driven by the shift of chemotherapy, infusion, and hemodialysis activities to outpatient centers. These chairs are valued for comfort during long sessions, stable positioning, safe transfers, and durability for high utilization, making them a key growth driver in the United States specialty medical chairs market. Models balancing recline range, transfer access, and durability are gaining preference.
Rehabilitation chairs held a 75.69% market share in 2025, reflecting their demand in skilled nursing, post-acute recovery, and long-term care settings. Extended daily use emphasizes pressure redistribution, bariatric capacity, and caregiver safety.
Fully electric chairs accounted for 65.55% of the United States specialty medical chairs market in 2025, driven by programmable positioning, enhanced ergonomics, and accessibility compliance. These systems reduce caregiver strain and support multiple workflows, maintaining their strong position across hospitals, DSOs, and outpatient sites.
Hydraulic and semi-electric chairs, with a projected 7.99% CAGR through 2031, cater to cost-sensitive settings requiring height adjustability without premium connectivity. Manual chairs remain relevant in home care and home dialysis but are expected to see reduced facility-based applications. Maintenance visibility and service simplicity are becoming critical purchase factors.